# An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

> **NCT00292084** · PHASE2 · COMPLETED · sponsor: **BioWest Therapeutics Inc** · enrollment: 60 (—)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Celgosivir

## Key facts

- **NCT ID:** NCT00292084
- **Lead sponsor:** BioWest Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 60 (—)
- **Last updated:** 2008-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00292084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00292084, "An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00292084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*